Drug
Mk0928
Mk0928: highest development phase Phase 3, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK0928, gaboxadol / Duration of Treatment - 6 weeks NCT00094666 | Phase 3 | Primary Insomnia |
Latest
No recent events.
Follow Mk0928 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.